ESYT1 and breast cancer: These findings indicate that E-Syt1 and E-Syt2 knockdown attenuate cell viability in ER+ breast cancer MCF7 and TNBC MDA-MB-231 and BT20 cells without having any effect on non-tumoral cells or the ER+ tumoral cell line T47D.